This special surveillance (H3E-JE-HS01, PMS non-interventional) case, concerns a 72 year-old male. The patient 
was diagnosed with king adenocarcinorna stage 4 on unknown date with metastases to brain. He had no medical 
history. He was an ex-smoker (20 cigarettes per day for 35 years). He was concurrently suffering from pneumonia, 
sputumbloody, hyerlipidaernia, hypertension, cough, brain metastases, prostatic hypertrophy, constipation and 
anaemia. He had radiotherapy for the brain metastases from 26-Aug-2009 to 29-Aug-2009. Concomitant 
included folic acid and vitamin B12. His performance status before the chemotherapy was one. On 01-
Sep-2009, his C-reactive protein (CRP) was 17.83mg/dL and platelet count (PLT) was 258000/mm3. The patient 
received intravenous pemetrexed disodium (Alimta.) 850mg in combination with carbopiatin 680mg for lung 
acienocarcinoma (stage 4) beginning on 04-Sep-2009. On 18-Sep-2009, he developed platelet count decreased 
(reported as non-serious) with PLT 149000/mm3. On days after receiving pemetrexed and 
carboplatin, he developed pleurisy, which was reported as serious for hospitalization or prolonged hospitalization, 
and he was treated with levofloxacin. After that, he received treatment with meropenem hydrate (24-Sep-2009 to 
Print Time: 02-SEP-2014 11:09 AM If a field is blank, there is no data for that field Page 422  of 661 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
041010,2009) and c ime hydrate and dindarnycin phosphate (07-Oct-2009 to 13-Oct-2009). On  
phis CRP was 30.S2rng/dL and PLT was 169000/mm3. On 13-Oct-2009, the pleurisy improved with CRP 
0.65ing/dt... Pemetrexed and carbeplatin were continued but both drugs were discontinued due to disease 
progression on 25-Jan-2010. The pulm    0  st assessed the event as related to pemetrexed and carboplatin. No 
ftalher information will be obtained. Case dosed.